Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Doxirazole vs Dexilant (Dexlansoprazole) 60 mg
NCT02529787Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Feb 2013
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Peak Plasma Concentration at 12 hours, Area Under the Curve to last measurable concentration at 12 hours and 1 more. Started Feb 2013; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02529787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529787.